FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Female contraceptives are numerous and varied, but male options are limited. There’s the common condom and at the other end of the spectrum is the extreme surgical solution in vasectomy. A new type of contraceptive is supposed to change all of that by being safe, is 98% effective, and only costs $10. Unfortunately, it seems big drug companies have expressed minimal interest in the revolutionary medical discovery.
The contraceptive in question is called Reversible Inhibition of Sperm Under Guidance (RISUG) and it was made by Indian biomedical engineer Sujoy Guha, Futurism reports. It’s revolutionary in that in not only provides men with a safe, effective, and affordable way to be reproductively responsible, it also takes a lot of the pressure off women.
For decades, women had the substantial burden of making sure that they didn’t get pregnant and many of them suffered greatly due to some of the side-effects. In contrast, men only had to make sure to bring a condom and the only problem with that option is the reduced sensation during sexual intercourse. The disparity could not be clearer in that scenario alone.
With RISUG, Guha created something that should have been a financial hit. Unfortunately, he found that big pharma was just not willing to risk spending potentially hundreds of millions of dollars on a single male contraceptive.
As to how the contraceptive works, it’s basically like a filter that is injected into the tracks that allow semen and sperm to travel from the scrotum to the urethra. It involves only one shot to let the semen through while preventing sperm cells from exiting. The result is sexual pleasure without the stress.
Fortunately, the birth control method is in its final stages in testing in India, Bloomberg recently reported. Once it is given the green light, it could hit the market in less than two years.
